BPC-157 TB-500: Questions From the Record, Answered

Frequently asked questions

These are the most common BPC-157 TB-500 questions, each answered from the published record and cited where the answer makes a quantitative claim. Where the literature is silent — most often on the combination itself — the answer says so plainly.

What is the BPC-157 and TB-500 blend used for in research?

Preclinical (mostly rodent) research on the two constituents covers wound and soft-tissue healing, tendon, ligament, muscle and bone repair, and angiogenesis ^[1][5][7]. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study ^[9].

Does the BPC-157 TB-500 blend help wound healing?

In animal wound models, Thymosin Beta-4 (TB-500's parent) increased re-epithelialization about 42% at 4 days and up to 61% at 7 days versus saline, with more wound contraction, collagen, and angiogenesis ^[5], and BPC-157 shows multi-tissue cytoprotection ^[1]. These are preclinical, single-compound results; the blend has no controlled wound-healing trial ^[9].

How much BPC-157 and TB-500 should be used per week?

There is no validated weekly amount for the blend. Underlying rodent studies used a wide range of single-compound dosing (e.g. BPC-157 around 10 microg/kg or 10 ng/kg in tendon models) ^[1]; community "loading then maintenance" protocols and fixed-ratio vials have no controlled-trial basis ^[9]. This is research context, not a human-use instruction.

What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 ^[3]. The "Wolverine" blend pairs the two as a research-community tissue-repair stack.

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157's local angiogenic and cytoprotective signal ^[2] is paired with TB-500's cytoskeletal cell-migration signal ^[3], so the two are proposed to cover different stages of tissue repair. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint ^[9].

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human, "no clinical safety data") makes no mention of TB-500 or combination use ^[9]. "Synergy" is an extrapolation from each peptide's separate mechanism.

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither constituent is FDA-approved and the blend has no approved indication. FDA placed both in 503A Category 2, effective September 29, 2023, identifying them as potentially presenting significant safety risks ^[13]. Both are WADA-prohibited (BPC-157 under S0; TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories).

Are there human clinical trials on the BPC-157 + TB-500 combination?

None. There are no controlled clinical trials of the combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies ^[11]; "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide ^[4].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures and enhanced tendon-fibroblast outgrowth ^[1]. These are preclinical, single-compound results, not human or combination evidence.

Does BPC-157 and TB-500 help muscle tears and recovery?

Preclinical work attributes tissue-repair and cell-migration activity to both constituents in animal models ^[1][4], but findings are single-compound and the blend itself has no controlled muscle-recovery trial. Online "rapid healing of any injury" claims outrun the published, animal-model evidence ^[10].

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4. X-ray crystallography established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization ^[3].

How does BPC-157 work compared to TB-500?

BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS up-regulation, nitric-oxide modulation, growth-hormone-receptor sensitization of tendon fibroblasts) ^[2]; TB-500 supplies an intracellular actin-sequestration signal (1:1 G-actin binding via the LKKTETQ motif) that regulates cell migration ^[3]. They act through complementary but largely non-overlapping pathways.

What is the half-life of BPC-157 and TB-500?

No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study ^[9]; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide ^[4].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed ^[8]. This is research-handling context, not a human-use instruction.

How often should you inject BPC-157 and TB-500?

There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing (e.g. Thymosin Beta-4 at 150 micrograms twice weekly intraperitoneally for 6 months in one model) ^[4]; community "loading then maintenance" protocols have no controlled-trial basis ^[9].

What are the side effects of BPC-157 and TB-500?

Long-term human safety is unknown for both constituents and the blend ^[10][11]. The principal documented concern is a tumor signal: Thymosin Beta-4 is implicated in metastasis and tumor angiogenesis, so the same pro-angiogenic, pro-migratory properties that aid repair could theoretically support tumor progression ^[4]. Combining two unapproved peptides compounds the uncertainty.

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 has been implicated in tumor metastasis and angiogenesis in tumor models; this is a theoretical safety consideration, not a demonstrated cancer-causing effect of TB-500 in humans ^[4]. No human data establish either safety or harm for the TB-500 fragment in this respect.

What is the difference between BPC-157 and TB-500?

They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide from a gastric-juice protein acting via VEGFR2/NO and growth-hormone-receptor pathways ^[2]; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting by sequestering G-actin ^[3]. Different sequences, sizes, and mechanisms.

How do you cycle BPC-157 and TB-500?

No validated cycle exists. Community "loading then maintenance" blend protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no basis in controlled human trials and should not be presented as validated dosing ^[9]. Underlying study durations vary widely by model ^[4].

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

In preclinical models, yes, by separate routes: BPC-157 up-regulates VEGFR2 and promotes its internalization with downstream Akt-eNOS signaling (increased vessel density, faster blood-flow recovery in ischemic rat muscle) ^[2]; Thymosin Beta-4 promotes angiogenesis alongside wound healing in rodents ^[7]. No controlled combination study has measured their combined angiogenic effect ^[9].

Is TB-500 bad for your heart?

Human data on TB-500's parent protein, full-length Thymosin Beta-4, come from intravenous Phase 1 studies that reported it well tolerated ^[4]; however, no controlled cardiac-safety data exist for the TB-500 heptapeptide itself or for the Wolverine blend, so cardiac safety is unestablished.

Is Wolverine legal?

Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved indication; both constituents are currently in FDA 503A Category 2, so they are not within FDA's compounding enforcement discretion ^[13]. Both are scheduled for FDA PCAC evaluation in July 2026 ^[15]. This is general regulatory information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

Compounding generally requires a licensed-prescriber evaluation (telehealth can be the front-end channel), a valid prescription, and a 503A or 503B facility ^[14]. But ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding, and BPC-157 is currently in Category 2 ^[13][14]. This is general regulatory information, not medical advice.

What is the FDA 503A status of Wolverine?

Both constituents are in FDA 503A Category 2, effective with the September 29, 2023 update to FDA's nominated-substances list — FDA identified them as potentially presenting significant safety risks, so they are not within its compounding enforcement-discretion policy ^[13]. Both are on the July 23-24, 2026 PCAC agenda for evaluation ^[15].